Piper Sandler Downgrades Antares Pharma (ATRS) to Neutral

Piper Sandler analyst David Amsellem downgraded Antares Pharma (NASDAQ: ATRS) from Overweight to Neutral with a price target of $5.60 (from $6.00).

For an analyst ratings summary and ratings history on Antares Pharma click here. For more ratings news on Antares Pharma click here.

Shares of Antares Pharma closed at $5.58 yesterday.

You May Also Be Interested In

• Wells Fargo Downgrades Roku Inc. (ROKU) to Equal Weight
• Wolfe Research Downgrades T-Mobile (TMUS) to Peerperform
• Apollo Hospitals (APLH:IN) PT Raised to INR8,500 at ICICI Securities